[1]石少庆.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果[J].医学信息,2023,36(01):152-154.[doi:10.3969/j.issn.1006-1959.2023.01.032]
　SHI Shao-qing.Clinical Effect of Apatinib Mesylate Tablets in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(01):152-154.[doi:10.3969/j.issn.1006-1959.2023.01.032]
点击复制

甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年01期
页码:
152-154
栏目:
药物与临床
出版日期:
2023-01-01

文章信息/Info

Title:
Clinical Effect of Apatinib Mesylate Tablets in the Treatment of Advanced Non-small Cell Lung Cancer
文章编号:
1006-1959（2023）01-0152-03
作者:
石少庆
（佳木斯市肿瘤结核医院肿瘤五科，黑龙江 佳木斯 154007）
Author(s):
SHI Shao-qing
(The Fifth Department of Oncology,Jiamusi Tumor Tuberculosis Hospital,Jiamusi 154007,Heilongjiang,China)
关键词:
甲磺酸阿帕替尼片; 晚期非小细胞肺癌; 癌胚抗原; 细胞角蛋白19片段
Keywords:
Apatinib Mesylate tablets; Advanced non-small cell lung cancer; Carcinoembryonic antigen; Cytokeratin 19 fragment
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.01.032
文献标志码:
A
摘要:
目的 观察甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果。方法 选取2020年7月-2021年7月在我院诊治的48例晚期非小细胞肺癌患者为研究对象，采用随机数字表法分为对照组和观察组，各24例。对照组采用常规化疗，观察组在对照组基础上给予甲磺酸阿帕替尼片治疗。比较两组治疗总有效率、肿瘤标记物水平[癌胚抗原（CEA）、细胞角蛋白19片段（CYFRA21-1）、血管内皮生长因子（VEGF）]、卡氏健康评分、中位生存时间及不良反应发生率。结果 观察组治疗总有效率为91.67%，高于对照组的83.33%（P＜0.05）；两组CEA、CYFRA21-1、VEGF水平均低于治疗前，且观察组低于对照组（P＜0.05）；两组卡氏健康评分均高于治疗前，且观察组高于对照组（P＜0.05）；观察组中位生存时间长于对照组（P＜0.05）；观察组不良反应发生率为16.67%，低于对照组的29.16%（P＜0.05）。结论 甲磺酸阿帕替尼片治疗晚期非小细胞肺癌效果确切，可减少肿瘤标志物的表达、提高卡氏健康评分、延长患者中位生存时间、降低不良反应发生率，是一种安全、有效的治疗药物。
Abstract:
Objective To observe the clinical effect of apatinib mesylate tablets in the treatment of advanced non-small cell lung cancer.Methods A total of 48 patients with advanced non-small cell lung cancer diagnosed and treated in our hospital from July 2020 to July 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 24 cases in each group. The control group was treated with conventional chemotherapy, and the observation group was treated with apatinib mesylate tablets on the basis of the control group. The total effective rate, tumor marker levels [carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), vascular endothelial growth factor (VEGF)], Karnofsky health score, median survival time and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 91.67%, which was higher than 83.33% in the control group (P<0.05). The levels of CEA, CYFRA21-1 and VEGF in the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05). The KPS scores of the two groups were higher than those before treatment, and the observation group was higher than the control group (P<0.05). The median survival time of the observation group was longer than that of the control group (P<0.05). The incidence of adverse reactions in the observation group was 16.67%, which was lower than 29.16% in the control group (P<0.05).Conclusion Apatinib mesylate tablets are effective in the treatment of advanced non-small cell lung cancer, which can reduce the expression of tumor markers, improve the Karnofsky health score, prolong the median survival time of patients, reduce the incidence of adverse reactions. It is a safe and effective treatment drug.

参考文献/References:

[1]张春雨.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的效果观察[J].吉林医药学院学报,2019,7(4):99-101.[2]朱国荣,卞杰.甲磺酸阿帕替尼片在晚期非小细胞肺癌患者治疗中的有效性和安全性评价[J].黔南民族医专学报,2020,9(3):53-56.[3]刘凯,郭天利,庞慧,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床分析[J].黑龙江医学,2019,43(5):431-432.[4]王雅婕,秦博宇,胡毅.甲磺酸阿帕替尼与多西他赛治疗晚期非小细胞肺癌的疗效比较[J].解放军医学院学报,2018,39(5):365-368．[5]张明晖,孙雅丽,杨艳,等.甲磺酸阿帕替尼联合埃克替尼治疗埃克替尼耐药的非小细胞肺癌的效果分析[J].癌症进展,2019,17(7):60-62,69．[6]张斌.序贯培美曲赛与联合阿帕替尼治疗EGFR-TKI获得性耐药晚期NSCLC的疗效比较[J].实用癌症杂志,2019,25(5):70-73.[7]李小江,姜珊,郭姗琦,等.阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察[J].中国肿瘤临床,2017,7(14):214-216．[8]Yan X,Wang Q,Wang H,et al.Apatinib as maintenance therapy in extensive-stage small-cell lung cancer:results from a single-center retrospective study[J].J Cancer Res Clin Oncol,2018,8(2):138-144．[9]曹军丽,王欣,郑磊,等.阿帕替尼联合替吉奥胶囊一线治疗晚期非小细胞肺癌的效果观察[J].中国综合临床,2019,35(3):221-226．[10]汉景红.阿帕替尼联合培美曲塞与顺铂治疗非鳞 NSCLS效果观察[J].西南国防医药,2019,29(2):40-42．[11]Fengying W,Shijia Z,Anwen X,et al.A phase Ⅱ clinical trial of apatinib in pretreated advanced non-squamous non-small-celllung cancer[J].Clin Lung Cancer,2018,5(1):14-17．[12]田牛,范韵鑫,张景熙,等.甲磺酸阿帕替尼治疗进展期晚期非小细胞肺癌临床疗效观察与分析[J].国际呼吸杂志,2018,38(12):904-909．[13]王雅婕,秦博宇,胡毅.甲磺酸阿帕替尼与多西他赛治疗晚期非小细胞肺癌的疗效比较[J].解放军医学院学报,2018,39(5):7-10,14．[14]徐聪.甲磺酸阿帕替尼片联合依托泊苷胶囊三线及三线以上治疗晚期小细胞肺癌的前瞻性、单臂、Ⅱ期临床研究[D].郑州:郑州大学,2020.

相似文献/References:

[1]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
　ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(01):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[2]党升强,崔立春,魏 琳,等.同步放化疗联合扶正肺癌方治疗局部晚期非小细胞肺癌的效果[J].医学信息,2019,32(24):166.[doi:10.3969/j.issn.1006-1959.2019.24.061]
　DANG Sheng-qiang,CUI Li-chun,WEI Lin,et al.Effect of Concurrent Chemoradiotherapy and Fuzheng Lung Cancer Recipe on Locally Advanced Non-Small Cell Lung Cancer[J].Journal of Medical Information,2019,32(01):166.[doi:10.3969/j.issn.1006-1959.2019.24.061]
[3]刘志坚,刘海燕,宿抱玉.阿帕替尼联合多西他赛治疗晚期非小细胞肺癌疗效和安全性的Meta分析[J].医学信息,2021,34(07):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
　LIU Zhi-jian,LIU Hai-yan,SU Bao-yu.Meta-analysis of the Efficacy and Safety of Apatinib Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(01):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
[4]史建强,胡 云.扶正解毒汤辅助克唑替尼对晚期非小细胞肺癌患者临床疗效及对血清肿瘤标志物的影响[J].医学信息,2023,36(16):137.[doi:10.3969/j.issn.1006-1959.2023.16.027]
　SHI Jian-qiang,HU Yun.Clinical Efficacy of Fuzheng Jiedu Decoction Combined with Crizotinib in the Treatment of Patients with Advanced Non-small Cell Lung Cancer and its Effect on Serum Tumor Markers[J].Journal of Medical Information,2023,36(01):137.[doi:10.3969/j.issn.1006-1959.2023.16.027]
[5]徐怡英.程序性死亡蛋白-1抑制剂治疗晚期非小细胞肺癌的临床疗效及安全性[J].医学信息,2023,36(23):115.[doi:10.3969/j.issn.1006-1959.2023.23.029]
　XU Yi-ying.Clinical Efficacy and Safety of Programmed Death Protein-1 Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(01):115.[doi:10.3969/j.issn.1006-1959.2023.23.029]

更新日期/Last Update: 1900-01-01